Orchid gets USFDA nod for Ceftriaxone

Orchid Chemicals & Pharmaceuticals has received the USFDA nod for its generic Ceftriaxone ANDA (Abbreviated New Drug Application). The Ceftriaxone injection is produced in a 250mg, 500mg, 1gm and 2gm single-dose vials, 1gm and 2gm piggyback vials and 10gm/100 ml pharmacy bulk package vials.

According to a release issued by Orchid to the BSE, the company has tied up with Apotex Corp to distribute its Ceftriaxone generic formulations in the US.

Ceftriaxone is an injectable third generation cephalosporin antibiotic, and the estimated annual retail sales of this product was around $700 million prior to patent expiry.